ERBB2 and gastroesophageal junction adenocarcinoma: The results of the SPOTLIGHT trial are expected to drive the widespread use of zolbetuximab for treating CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma patients, leading to a significant increase in economic burden that will certainly become an important issue for healthcare decision-makers.